Application note: Workflow for high-throughput glycoprofiling of rituximab
Posted: 1 November 2022 | Merck | No comments yet
Protocol for purification, reduction, and SEC-MS glycoform analysis of a therapeutic monoclonal antibody (mAb)
Discover in this application note the complete SEC-MS workflow, developed to enable rapid glycoprofiling of monoclonal antibodies (mAbs) in cell culture supernatants. It includes:
- Antibody (mAb) purification using immobilised protein A
- Antibody reduction procedure
- Mass spectrometer calibration
- System suitability test utilising a recombinant human monoclonal antibody reference
- Size exclusion chromatography – mass spectrometry (SEC-MS) method for sample separation and analysis.
Related content from this organisation
- Moderna-Merck & Co cancer vaccine with Keytruda shows late-stage promise
- Raman-based PAT tool could advance continuous vaccine manufacturing
- Merck acquires JSR Life Sciences chromatography business
- MSD acquisition to accelerate first-in-class COPD drug
- Next drug patent cliff to challenge Big Pharma strategy
Related topics
Biopharmaceuticals, Formulation, Manufacturing, QA/QC, Research & Development (R&D)
